Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America

To read the full story

• Sign In
• Subscribe

Related Article

• Otsuka Accelerates Pipeline Investment Centered on “Next 8” as Growth Drivers
  August 1, 2025

• Otsuka Achieves 2-Digit Growth Driven by Core Products
  February 17, 2025

• Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
  August 2, 2024

• Otsuka’s Q1 Pharma Sales Zoom 16.2% on Global Brands
  May 1, 2024

• Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
  February 15, 2024

• Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
  August 1, 2023

• Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
  May 15, 2023

• Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
  February 15, 2023

• Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
  November 1, 2022

• Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub
  May 16, 2022

• Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
  February 14, 2022

• Otsuka’s 4 Global Brands Likely to Hit 480 Billion Yen, 2 Years Earlier
  August 10, 2021

• Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
  May 14, 2021

• Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
  February 15, 2021

• Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
  November 16, 2020

• Otsuka’s 1st Half Pharma Sales Rise 7.6% as 4 Global Brands Fare Well
  August 11, 2020

• Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
  May 29, 2020

• Otsuka’s Pharma Biz Zooms 14.0% in January-September on 4 Global Brands
  November 14, 2019

• Otsuka Rings Up Double-Digit Growth in H1 Pharma Sales
  August 9, 2019

• Upbeat Global Brands Drive Otsuka Sales in 2018
  February 14, 2019